To see the other types of publications on this topic, follow the link: 625.807 2.
Journal articles on the topic '625.807 2'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '625.807 2.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Felten, R., L. Widawski, L. Spielmann, C. Gaillez, W. Bao, J. E. Gottenberg, P. M. Duret, and L. Messer. "POS1065 IMPACT OF HYPERURICEMIA ON CLINICAL PHENOTYPE, COMORBIDITIES, AND RESPONSE TO SECUKINUMAB IN PSORIATIC ARTHRITIS: POST HOC ANALYSIS OF FUTURE AND MAXIMISE STUDIES." Annals of the Rheumatic Diseases 81, Suppl 1 (May 23, 2022): 855.1–855. http://dx.doi.org/10.1136/annrheumdis-2022-eular.807.
Full textAbstract:
BackgroundHyperuricemia (HU) is a metabolic abnormality associated with psoriasis (PsO) and psoriatic arthritis (PsA)1. The prevalence of HU is 2–13% in general population, 19–20% in PsO patients (pts), and 27–32% in PsA pts1,2. Pts with PsO/PsA are at significantly increased risk of HU and development of gout1. The pathogenic role of chronic HU in the development and maintenance of PsA is based on epidemiological, clinical, and fundamental arguments and hence does not appear fortuitous. These processes can influence each other3. Moreover, PsA with HU has been shown to be more peripheral, destructive, and challenging to treat4.ObjectivesTo evaluate the impact of HU on PsA in terms of clinical presentation, severity, comorbidities, and response to secukinumab (SEC) over 1-year.MethodsThis post hoc analysis included pooled data from PsA pts enrolled in the FUTURE 2–5 and MAXIMISE phase 3 trials. Pts were stratified into 2 groups based on baseline (BL) serum uric acid (SUA) level (HU: ≥360 µmol/L; without HU: <360 µmol/L and no history of gout and/or uric acid lowering therapies [ULT]). Demographic and disease characteristics, PsA and therapeutic history, and comorbidities data, were collected at BL. Evaluations included ACR20/50/70 responses, Psoriasis Area and Severity Index (PASI) 90 response, resolution of enthesitis and dactylitis, Health Assessment Questionnaire Disability Index (HAQ-DI), and mean change in SUA level, up to Week 52. All analyses were performed at a descriptive level and data presented as observed.ResultsOverall, 2504 PsA pts were included in the analysis, of which 822 (32.8%) had HU (62 [2.5%] with gout; 49 [2.0%] treated with ULT). At BL, pts with HU were mostly male (76.0% vs 34.2%) and had a higher body mass index (30.9 vs 28.3 kg/m2) with more comorbidities, such as hypertension (43.8% vs 31.3%), compared to pts without HU. A higher proportion of pts with HU had dactylitis (34.5% vs 25.9%), and PsO (48.3% vs 36.3%) with a greater mean PASI score (13.6 vs 10.2), compared to pts without HU (Table 1). The proportion of pts achieving ACR50, resolution of enthesitis/dactylitis, and mean change in HAQ-DI score were comparable up to Week 52 irrespective of BL HU status. The PASI90 response rate was higher in pts without HU with SEC 150 mg (with and without load) and similar in SEC 300 mg group irrespective of BL HU status (Figure 1).Table 1.Demographics and baseline characteristicsParameters, mean ± SD unless specifiedWith hyperuricemia (N=822)Without hyperuricemia (N=1682)Age (Years)48.5 ± 12.4148.3 ± 12.19Gender (Male), n (%)625 (76.0)576 (34.2)Weight (kg)92.71 ± 18.6279.59 ± 17.55BMI (kg/m2)30.90 ± 5.8628.33 ± 5.91History of hypertension, n (%)360 (43.8)526 (31.3)History of diabetes mellitus, n (%)85 (10.3)144 (8.6)TJC20.6 ± 15.5221.3 ± 16.25SJC10.9 ± 9.3110.8 ± 9.13Enthesitis, n (%)412 (50.1)852 (50.7)Dactylitis, n (%)284 (34.5)436 (25.9)Evidence of current psoriasis; n (%)397 (48.3)611 (36.3)Mean PASI score*13.61 ± 11.0310.16 ± 9.13TNFi naїve, n (%)477 (58.0)938 (55.8)MTX use at randomization, n (%)321 (39.1)685 (40.7)Serum uric acid (µmol/L)420.7 ± 57.11274.9 ± 51.98CRP (mg/L)11.6 ± 18.6610.7 ± 23.36*not collected in MAXMISEBMI, body mass index; CRP, C-reactive protein; MTX, methotrexate; SJC, swollen joint count; TJC, tender joint count; TNFi, tumor necrosis factor inhibitorConclusionIn this pooled analysis of SEC PsA studies, pts with HU reported a higher prevalence of hypertension, with more clinical dactylitis, and more PsO, with higher PASI score compared to pts without HU. Efficacy across all musculoskeletal manifestations was similar with SEC 150 and 300 mg; while PASI90 response rate was slightly better in patients without HU with SEC 150 mg, and similar with SEC 300 mg irrespective of HU status, at 1-year.References[1]Tripolino C, et al. Front Med. 2021;8:737573[2]AlJohani R, et al. J Rheumatol. 2018;45(2):213–7[3]Felten R, et al. Clin Rheumatol. 2020;39:1405–13[4]Widawski L, et al. Clin Rheumatol. 2022. https://doi.org/10.1007/s10067-022-06061-xDisclosure of InterestsRenaud FELTEN Consultant of: Novartis (Advisory board), Laura Widawski: None declared, Lionel Spielmann: None declared, Corine Gaillez Shareholder of: Novartis, Employee of: Novartis, Weibin Bao Shareholder of: Novartis, Employee of: Novartis, Jacques-Eric Gottenberg Consultant of: Novartis (Advisory board), Pierre-Marie Duret: None declared, Laurent Messer: None declared
2
Vásárhelyi, Barna, Katalin Kristóf, Eszter Ostorházi, Dóra Szabó, Zoltán Prohászka, and Béla Merkely. "A specifikus IgM- és IgG-antitesteket detektáló gyorstesztek értéke a SARS CoV-2 vírusfertőzés kimutatásában (A COVID–19-pandémia orvosszakmai kérdései)." Orvosi Hetilap 161, no. 20 (May 2020): 807–12. http://dx.doi.org/10.1556/650.2020.31859.
Full textAbstract:
Absztrakt: Bevezetés: 2020. március végén a SARS-CoV-2-vírusfertőzöttség (COVID–19-betegség) diagnosztizálására megjelentek Magyarországon a vírussal szembeni specifikus antitestek jelenlétét kimutató gyorstesztek. Célkitűzés: Munkánkban két gyorsteszt, az Anhui és a Clungene teszt diagnosztikai teljesítményét értékeltük a fertőzés kimutatásában arany standardnak számító ’real-time’ (valós idejű) PCR (a továbbiakban: PCR) vizsgálati eredmények alapján. Módszer: 2020. március 16. és április 14. között intézetünk 20 120, COVID–19-fertőzéssel kapcsolatos rekordot küldött be az országos adatszolgáltató rendszeren keresztül. Ebben 4140 személynél csak IgM és IgG jelenlétét kimutató gyorstesztvizsgálat történt; 3210 személynél csak PCR-teszt, 1654 személynél pedig PCR- és gyorstesztvizsgálat (Anhui: 625, Clungene: 1029) végzésére maximum 3 nap eltéréssel is sor került. PCR-pozitívnak azt a személyt tekintettük, akinél bármikor PCR-pozitivitás fordult elő, illetve antitestpozitívnak azt, akinél IgM- és/vagy IgG-pozitivitást észleltünk. (Megjegyzés: a Clungene tesztet Lungene néven is forgalmazzák.) Eredmények: A 4864, PCR-rel vizsgált személy közül 308 volt PCR-pozitív (a PCR-pozitivitás prevalenciája 6,3% volt). A PCR alapján az Anhui gyorsteszt szenzitivitása 33,3%, specificitása 72,85%; a Clungene gyorsteszt szenzitivitása 35,48%, specificitása 85,02% volt. 6%-os PCR-pozitivitási prevalencia esetén a pozitív és a negatív prediktív érték az Anhui gyorsteszt esetében 7,28%, illetve 94,48%, míg a Clungene gyorsteszt esetében 13,13%, illetve 95,38% volt. Következtetés: Az aktuális fertőzöttségi prevalencia melletti alacsony pozitív prediktív értékek alapján az általunk értékelt gyorstesztek jelenleg nem alkalmasak a SARS-CoV-2-vírusfertőzöttség (PCR-pozitivitás) kimutatására az általános populációban. Az Anhui és a Clungene gyorstesztek negatív eredményei a jelenlegi 6%-os prevalencia mellett mintegy 95%-os valószínűséggel jelzik a SARS-CoV-2-vírusexpozíció hiányát. Az Anhui és a Clungene – SARS-CoV-2 vírus elleni IgM- és IgG-antitesteket kimutató – gyorstesztek alkalmazása a COVID–19-fertőzés differenciáldiagnosztikájában szakmailag vállalhatatlan. Orv Hetil. 2020; 161(20): 807–812.
3
Steiner, R., A. Angerhofer, and H. Scheer. "The Photosynthetic Apparatus of Ectothiorhodospira halochloris 2. Accessibility of the Membrane Polypeptides to Partial Proteolysis and Antenna Polypeptide Assignments to Specific Chromophores." Zeitschrift für Naturforschung C 41, no. 5-6 (June 1, 1986): 571–78. http://dx.doi.org/10.1515/znc-1986-5-614.
Full textAbstract:
E. halochloris thylakoids and spheroplasts were treated with trypsin, thermolysin or proteinase K to determine which proteins are exposed at the different membrane surfaces. Based on SDS polyacrylamide analysis, all 9 polypeptides are exposed on the cytoplasmic side. Only one (28 kDa) is accessible from the periplasmic side. This polypeptide is generally isolated as the H-subunit of the reaction centers of photosynthetic bacteria, but is in the case of E. halochloris rather isolated with the antenna (B 800/1020) (Steiner and Scheer, Biochim . Biophys. Acta 807, 278, 1983).Proteolysis is accompanied by a shift of the absorption band at longest wavelengths from 1020 to 960 nm (B 800/960), which upon standing is shifted further to 680 nm (“B” 800/680). The spectral changes are similar to the ones reported earlier for treatment with acid, and are also inducible with urea. The correlation of SDS-PAGE and absorption spectroscopy shows, that the chroophores absorbing at 1020 nm are transformed sim ultaneously with the degradation of the 6.5 kDa (=α) polypeptide.
4
Kim, Min Jung, and Dong Bok Lee. "Corrosion of Inconel 625 at 600-800°C in N2/H2O/H2S Atmospheres." Advanced Materials Research 1025-1026 (September 2014): 591–96. http://dx.doi.org/10.4028/www.scientific.net/amr.1025-1026.591.
Full textAbstract:
Ni-base Inconel 625 alloys with a composition of 58.9Ni-22Cr-9Mo-5Fe 3.5Nb-0.4Si-0.4Mn-0.4Al-0.4Ti (wt.%) corroded at 600, 700 and 800 °C for up to 30 h in 1 atm of N2/H2O/H2S-mixed gases. They corroded fast owing to the formation of sulfides and the presence of hydrogen and water vapor in the gas. Triple layered scales formed. Nickel corroded to NiS to form the outer NiS layer, where Fe was dissolved. Chromium corroded to Cr-sulfides to form the middle layer. Other alloying elements such as Mo, Nb, Si, Mn, Al, and Ti corroded to form the inner layer that consisted primarily of intermixed sulfides and oxides. Since sulfides were present throughout the scale and hydrogen made the scale porous and fragile, Inconel 625 was nonprotective during high-temperature corrosion in N2/H2O/H2S gases.
5
Kweon, Suc-hyun, Jin sung Park, and Byung Ha Park. "Sarcopenia and Its Association With Change of Bone Mineral Density and Functional Outcome in Old-Aged Hip Arthroplasty Patients." Geriatric Orthopaedic Surgery & Rehabilitation 13 (January 2022): 215145932210928. http://dx.doi.org/10.1177/21514593221092880.
Full textAbstract:
Aim This study aimed to investigate the relationship between sarcopenia and change in bone mineral density (BMD) and functional outcome in hip arthroplasty patients. Methods: Among the 221 patients who had undergone hip arthroplasty, 147 patients were enrolled. All patients were divided into 2 groups according to presence of sarcopenia. Bone mineral density (BMD) at hospitalization and 1-year after surgery and Barthel index was measured at the time of before injury, hospitalization, 3 months and 1-year after surgery. Results: BMD at hospitalization showed .627 ± .082 (g/cm2) in Sarcopenia and .726 ± .059 (g/cm2) in Non-sarcopenia at femur (total) site ( P < .001), .531 ± .085 (g/cm2) vs .629 ± .057 (g/cm2) at femur neck site (P=.002), .715 ± .084 (g/cm2) vs .807 ± .058 (g/cm2) at lumbar (L1-L4) site ( P < .001). BMD at 1-year follow-up period, Sarcopenia showed .626 ± .082 (g/cm2) and Non-sarcopenia showed .725 ± .060 (g/cm2) at femur (total) site ( P < .001), .530 ± .085 (g/cm2) vs .629 ± .058 (g/cm2) at femur neck site ( P < .001), .715 ± .084 (g/cm2) vs .806 ± .058 (g/cm2) at lumbar (L1-L4) site ( P < .001). Change of BMD showed −.01 ± .25% for Sarcopenia and −.15 ± .47% for Non-sarcopenia in femur (total) site (P=.089), −.08 ± .63% vs −.01 ± 1.01% in femur neck site ( P = .058), .00 ± .09% vs −.12 ± .33% for each group in lumbar (L1-L4) site ( P = .052). Barthel index score showed 79.94 ± 5.66 for Sarcopenia and 84.74 ± 5.36 for Non-sarcopenia at pre-injury status ( P < .001), 33.89 ± 4.94 vs 33.87 ± 5.36 at the time of hospitalization ( P = .977), 57.42 ± 7.19 vs 60.06 ± 5.39 at 3 months follow up ( P = .015), 73.86 ± 5.94 vs 80.71 ± 4.81 for each group at 1-year follow up ( P < .001). Conclusions: Our study found that the sarcopenia showed lower BMD than the non-sarcopenia, but there was no significant difference of BMD change in the follow-up period. In addition, the sarcopenia showed poor functional results at all points except at the time of hospitalization.
6
Jayme, D. G., L. C. Gonçalves, R. M. Maurício, J. A. S. Rodrigues, N. M. Rodriguez, A. L. C. C. Borges, I. Borges, et al. "Avaliação pela técnica semiautomática de produção de gases das silagens de quatro genótipos de girassol (Helianthus annuus) (Rumbosol 91, Victoria 627, Victoria 807 e Mycogen 93338)." Arquivo Brasileiro de Medicina Veterinária e Zootecnia 61, no. 6 (December 2009): 1403–10. http://dx.doi.org/10.1590/s0102-09352009000600021.
Full textAbstract:
Foram avaliadas as silagens de quatro genótipos de girassol (Helianthus annuus) (Rumbosol 91, Victoria 627, Victoria 807 e Mycogen 93338), pela técnica semiautomática de produção de gases. O delineamento experimental utilizado foi o de blocos ao acaso, em esquema de parcelas subdivididas, sendo as médias comparadas pelo teste SNK (p<0,05). O genótipo Rumbosol 91 apresentou a maior produção acumulativa de gases para o tempo de 96 horas de incubação com valor de 128,47mL/g de MS, e o menor valor foi observado para o genótipo Victoria 807 com 92,88. Não foram observadas diferenças entre os valores de degradabilidade da matéria seca (DMS) para as silagens avaliadas nos diferentes tempos. O potencial máximo de produção de gases variou de 91,67 para o genótipo Victoria 807 a 125,46mL/g de MS para a silagem do genótipo Rumbosol 91. O genótipo Rumbosol 91 apresentou a maior DMS para as taxas de passagem de 2 e 5% com valores de 46,39 e 43,26%. O maior valor para taxa de passagem (8%) foi observado para o genótipo Victoria 627. As silagens dos genótipos Rumbosol 91 e Victoria 627 mostraram destacado potencial para produção de gases e taxa de produção de gases.
7
Boucher, Taryn Mary, Nancy E. Kemeny, Joanne F. Chou, Marinela Capanu, Maeve Aine Lowery, and Andrea Cercek. "Analysis of prior malignancies in patients with cholangiocarcinoma." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 305. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.305.
Full textAbstract:
305 Background: Cholangiocarcinomas account for approximately 3% of gastrointestinal tumors. Our aim was to analyze types of prior malignancies in patients (pts) with cholangiocarcinoma, with a special interest in pts with prior breast cancer. Methods: An IRB waiver was obtained to retrospectively review female pts who presented with an initial diagnosis of cholangiocarcinoma to Memorial Sloan Kettering Cancer Center between January 2000 and August 2015. Results: Medical records of 804 female pts were reviewed. After excluding pts with limited records or without biopsy-proven cholangiocarcinoma, a total of 625 pts were analyzed. Of 625 pts with cholangiocarcinoma, 506 (81%) were intrahepatic (ICC), 85 (14%) hilar, 24 (4%) extrahepatic and 10 (2%) mixed ICC and hepatocellular carcinoma or rare variant. The median age at cholangiocarcinoma diagnosis was 63 years [range: 16-97 years] and 82.7% were white. Of the 625 pts, 105 (17%) had a history of another cancer: 44 (7.04%) breast, 9 (1.44%) colon, 9 (1.44%) melanoma and 5 (0.8%) ovarian. The remaining 38 pts with various prior cancers were grouped as Other. There was no association between the site of cholangiocarcinoma (intrahepatic versus extrahepatic) and type of prior cancer (p = 0.26). In pts with a prior cancer (n = 105), the median time from diagnosis of prior cancer to cholangiocarcinoma was 76 months [range: 2-624 months], which did not differ among types of prior malignancies (p = 0.25). The interval between diagnosis of breast cancer and cholangiocarcinoma was 82 months [range 4-526 months]. In pts with prior breast cancer, 21 (48%) received radiation and 25 (57%) received chemotherapy for their breast cancer. In 22 pts who had ER/PR testing, 16 were ER positive and 15 were PR positive. In 17 pts who had HER2 testing, 4 were HER2 positive. Conclusions: In 625 female pts with cholangiocarcinoma, 17% had a history of another cancer, with 44 (7%) having a history of breast cancer. The apparent increase in proportions of prior breast cancer compared to other cancers should be investigated further. An analysis of tumor mutations (MSK-IMPACT) and germline mutations in pts with cholangiocarcinoma and a history of breast cancer is underway to determine a potential association of molecular factors.
8
Brandao, L. R., D. Dix, M. David, S. Israels, P. Massicotte, S. Williams, and A. K. Chan. "An Attempt to Reach Consensus Regarding Management of Neonatal Renal Vein Thrombosis: The Canadian Pediatric Hemostasis and Thrombosis Network Experience." Blood 104, no. 11 (November 16, 2004): 4026. http://dx.doi.org/10.1182/blood.v104.11.4026.4026.
Full textAbstract:
Abstract Background: Renal vein thrombosis (RVT) is the most frequent site of primary venous thrombosis in neonates. At present, there is no conventional therapeutic regimen for this condition. Objective: To establish current clinical guidelines based on data from the Canadian Pediatric Hemostasis and Thrombosis Network (CPHTN). Materials and Methods: A standardized questionnaire was sent to CPHTN members involved with pediatric thrombosis care. Clinical variables included thrombus location (unilateral vs. bilateral), severity (non-occlusive vs. occlusive), extension to the inferior vena cava (IVC+), and concomitant bleeding at diagnosis [i.e. hematuria with thrombocytopenia (H/T+), with/without ≥ grade 2 intraventricular hemorrhage (IVH+/−)]. Results: A total of 16 pediatric hematologists participated, with a response rate of approximately 80%. Regarding diagnostic imaging, the most utilized methods were the following: a) Doppler ultrasound (U/S) in 14/16 (87.5%); b) U/S without Doppler in 1/16 (6.25%); and c) contrast venography in 1/16 (6.25%). 12/16 (75%) of the physicians would have ordered a thrombophilia work up. For unilateral, non-occlusive, H/T− or H/T+ cases, management included, respectively: 1) no therapy in 11/16 (68.75%) and 9/16 (56.25%); 2) low-molecular-weight heparin (LMWH) in 2/16 (12.5%) (3-month-course) and 3/16 (18.75%) (14-day or 3-month course); and 3) therapy based on radiologic follow up (f/u) in 3/16 (18.75%) and 4/16 (25%). For unilateral, occlusive, H/T+, IVH− or IVH+ cases, management included: 1) no therapy in 5/16 (31.25%) and 10/16 (62.5%); 2) LMWH in 6/16 (37.5%) and 4/16 (25%); and 3) treatment based on f/u findings in 5/16 (31.25%) and 2/16 (12.5%). For bilateral, occlusive, IVC−, IVH− cases, management included: 1) LMWH (2 weeks to 3 months) in 12/16 (75%); 2) tissue-plasminogen activator (t-PA) in 1/16 (6.25%); 3) LMWH and t-PA in 2/16 (12.5%); and 4) therapy based on f/u in 1/16 (6.25%). Finally, for bilateral, occlusive, IVC+, IVH− or +, the responses were, in that order: 1) LMWH (6 weeks to 3 months) in 10/16 (62.5%) and 11/16 (68.75%); 2) t-PA in 3/16 (18.75%) and 0/16; 3) LMWH and t-PA in 2/16 (12.5%) and 0/16; 4) treatment based on f/u in 1/16 (6.25%) in both groups; 5) no therapy in 2/16 (12.5%) of the latter group only; and 6) unknown in 2/16 (12.5%) of the latter group only. The anti-Xa level (0.5 to 1.0 range) was the only assay suggested for monitoring LMWH. Standard heparin was monitored by anti-Xa levels in only 3/16 (18.75%) of cases. Consultation sources included 1) combined sources (i.e. books, protocols, journals) in 10/16 (62.5%) cases; 2) journals in 4/16 (25%) cases; and 3) 1-800-NO-CLOTS in 2/16 (12.5%) cases. 15/16 (93.75%) of the participating physicians supported the idea of developing therapeutic protocols. Conclusions: Currently, there are no standard therapeutic practices with respect to neonatal RVT. It would be difficult to successfully complete a randomized clinical trial due to small numbers. However, multicenter, prospective studies utilizing consistent therapeutic approaches would be extremely helpful in this clinical setting.
9
Chow, P. L., C. P. Ho, D. Kan, R. M. Attar, F. Graf Finckenstein, J. M. Carboni, S. M. Galbraith, F. Y. Lee, M. M. Gottardis, and B. S. Krishnan. "Effect of IGF-1R inhibitor BMS-754807 on tumor glucose metabolism and proliferation in Sal-IGF xenografts by FDG and FLT- PET imaging." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e14501-e14501. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e14501.
Full textAbstract:
e14501 Background: The type 1 insulin-like growth factor receptor (IGF-1R) plays a critical role in mitogenesis and survival in a variety of human tumor cells. IGF-1R is also closely related to the insulin receptor (IR). It is becoming increasingly evident that stimulation of IR or IR/IGF-1R hybrid receptors by insulin or IGF-1/2 may contribute to cancer growth, suggesting that both IGF-1R and IR may be targets for cancer therapy. BMS-754807 (‘807) is an oral IGF-1R tyrosine kinase antagonist under development that also blocks IR activity. This study explores the feasibility of fluorodeoxyglucose (FDG) and fluorothymidine (FLT) positron emission tomography (PET) as pharmacodynamic imaging biomarkers in a xenograft model. Methods: Mice were implanted with fragments of Sal-IGF, a transgenic salivary gland tumor expressing constitutively active IGF-1R. Once tumors reached desired size, the mice were divided into 3 treatment groups (vehicle, 6.25 mg/kg ‘807, & 50 mg/kg ‘807 on days 1–4). FDG-PET scans were performed on day -2 (prior to treatment), days 1 & 2 (max/min concentrations post day 1 dose), and days 4 & 5 (max/min day 4 dose). FLT-PET scans were performed on days -2, 2 (min day 1 dose), & 5 (min day 4 dose). Results: With FDG-PET imaging, a 66% reduction (P<0.05, paired t-test) in tumor SUVmean was observed at the end of the 50 mg/kg therapy (day 4) and sustained for 24h (day 5) with a concomitant reduction of 37% in tumor burden by day 5 (P<0.05). FLT-PET studies demonstrated a 45% reduction (P<0.05) in tumor SUVmean observed 24h after the end of 50 mg/kg therapy (day 5) with a concomitant reduction of 50% in tumor burden (day 5, P<0.05). Conclusions: Correlation with tumor growth inhibition suggests feasibility of FDG- PET despite IR blockade. These results support the use of both FDG and FLT PET imaging in clinical trials with ‘807. [Table: see text]
10
Lee, Hsin-Ying, Day-Shan Liu, Jen-Inn Chyi, Edward Yi Chang, and Ching-Ting Lee. "Lattice-Matched AlInN/GaN/AlGaN/GaN Heterostructured-Double-Channel Metal-Oxide-Semiconductor High-Electron Mobility Transistors with Multiple-Mesa-Fin-Channel Array." Materials 14, no. 19 (September 22, 2021): 5474. http://dx.doi.org/10.3390/ma14195474.
Full textAbstract:
Multiple-mesa-fin-channel array patterned by a laser interference photolithography system and gallium oxide (Ga2O3) gate oxide layer deposited by a vapor cooling condensation system were employed in double-channel Al0.83In0.17N/GaN/Al0.18Ga0.82N/GaN heterostructured-metal-oxide-semiconductors (MOSHEMTs). The double-channel was constructed by the polarized Al0.18Ga0.82N/GaN channel 1 and band discontinued lattice-matched Al0.83In0.17N/GaN channel 2. Because of the superior gate control capability, the generally induced double-hump transconductance characteristics of double-channel MOSHEMTs were not obtained in the devices. The superior gate control capability was contributed by the side-wall electrical field modulation in the fin-channel. Owing to the high-insulating Ga2O3 gate oxide layer and the high-quality interface between the Ga2O3 and GaN layers, low noise power density of 8.7 × 10−14 Hz−1 and low Hooge’s coefficient of 6.25 × 10−6 of flicker noise were obtained. Furthermore, the devices had a unit gain cutoff frequency of 6.5 GHz and a maximal oscillation frequency of 12.6 GHz.
11
Rakpanich, S., Piyachat Meejitpaisan, Sunantasak Ravangvong, and Jakrapong Kaewkhao. "Effect of Nd3+ Ion on Bismuth Borosilicate Glass Properties." Key Engineering Materials 702 (July 2016): 13–17. http://dx.doi.org/10.4028/www.scientific.net/kem.702.13.
Full textAbstract:
This paper reports neodymium doped bismuth borosilicate glasses in composition (40-x)B2O3-40Bi2O3-20SiO2-xNd2O3 where x = 0, 0.5, 1.0, 1.5, 2.0 and 2.5 mol%, have been prepared by melt quenching technique and are characterized through physical properties structural properties, optical absorption spectra and emission spectra measurements. The density is found to increase with the increase in concentration of Nd2O3. The molar volumes of glass decrease where concentration of Nd2O3 where concentration of Nd2O3 is 0-0.5 mol% and beyond 0.5 mol% that molar volumes were increased. The absorption spectra of Nd3+-doped glass centered at 512 nm (4I9/2→2K13/2+4G9/2), 526 nm (4I9/2→4G7/2), 584 nm (4I9/2→4G5/2+2G7/2), 625 nm (4I9/2→2H11/2), 681 nm (4I9/2→4F9/2), 747 nm (4I9/2→4F7/2+4S3/2), 804 nm (4I9/2→4F5/2+2H9/2) and 877 nm (4I9/2→4F3/2) have been observed. The emission spectra of glass were also investigated.
12
Calvo, Aitana, Saioa Alonso, Esther Prieto, Ana Ascaso-del-Rio, Jordi Ortuño, Nieves Fernandez, and Antonio Portolés. "Single and Multiple Dose PK–PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers." Journal of Clinical Medicine 11, no. 3 (February 6, 2022): 858. http://dx.doi.org/10.3390/jcm11030858.
Full textAbstract:
Carisoprodol was authorised in 1959 without a full pharmacokinetic–pharmacodynamic (PK–PD) characterisation. We designed a crossover, double-blind, placebo-controlled, randomized clinical trial to characterize the PKs of carisoprodol and its main active metabolite, meprobamate, after single (350 mg), multiple (350 mg/8 h, 14 days), and double (700 mg) doses of carisoprodol. Thirteen healthy volunteers were enrolled. After a single (350 mg) dose, the main carisoprodol parameters were (mean ± SD) Cmax: 2580 ± 1214 ng/mL, AUC0–∞: 8072 ± 6303 h·ng/mL, and half-life (T1/2): 2 ± 0.8 h. For meprobamate, the parameters were Cmax: 2181 ± 605 ng/mL and 34,529 ± 7747 h·ng/mL y 9 ± 1.9 h. Different profiles were found for extensive and poor 2C19 metabolizers. After 14 days of treatment (350 mg/8 h) the results for carisoprodol were (mean ± SD) Cmax: 2504 ± 730 ng/mL, AUC0–∞: 7451 ± 3615 h·ng/mL, and T1/2: 2 ± 0.7 h. For meprobamate (a steady state was reached), the parameters were Cmax: 5758 ± 1255 ng/mL and 79,699 ± 17,978 h·ng/mL y 8.7 ± 1.4 h. The study allowed for the full characterization of the pharmacokinetic profile of carisoprodol and meprobamate. Accumulation of meprobamate but not of carisoprodol was evident after 14 days of treatment.
13
Storb, R., RF Raff, FR Appelbaum, FW Schuening, BM Sandmaier, TC Graham, and ED Thomas. "What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624]." Blood 72, no. 4 (October 1, 1988): 1300–1304. http://dx.doi.org/10.1182/blood.v72.4.1300.1300.
Full textAbstract:
Abstract In view of reported attempts at marrow grafting after nuclear accidents with a broad range of radiation exposures, the present study explored the total-body irradiation (TBI) conditions needed for engraftment in a canine model by using marrow from DLA-identical littermates. Previous studies have shown that such grafts are consistently successful when recipients are exposed to 920 cGy of TBI delivered at a rate of 7 cGy/min from opposing dual cobalt sources. The present TBI doses were all in the lethal range. Five dogs were administered 450 cGy; seven dogs, 600 cGy; five dogs, 700 cGy; and five dogs, 800 cGy of TBI administered at 7 cGy/min. They received a median of 3.3 x 10(8) marrow cells/kg intravenously after completion of radiation. Results showed transient allogeneic marrow engraftment in all dogs administered the lowest dose of TBI studied (450 cGy). Importantly, transient grafts permitted four of five dogs to live long enough for autologous marrow recovery to occur. At increasing radiation doses, 600, 700, and 800 cGy, the risk of graft failure lessened, with 3 of 7, 2 of 5, and 1 of 5 dogs, respectively, showing graft rejection. Fewer dogs survived with autologous marrow recovery, and more showed sustained allogeneic engraftment (4 of 7, 3 of 5, and 4 of 5 dogs, respectively). We conclude that DLA-identical littermate marrow grafts are beneficial in the setting of otherwise lethal radiation exposures, with most dogs either experiencing sustained allogeneic engraftment or surviving with autologous marrow recovery due to the extended support provided by a transient allogeneic graft.
14
Storb, R., RF Raff, FR Appelbaum, FW Schuening, BM Sandmaier, TC Graham, and ED Thomas. "What radiation dose for DLA-identical canine marrow grafts? [published erratum appears in Blood 1989 Feb;73(2):624]." Blood 72, no. 4 (October 1, 1988): 1300–1304. http://dx.doi.org/10.1182/blood.v72.4.1300.bloodjournal7241300.
Full textAbstract:
In view of reported attempts at marrow grafting after nuclear accidents with a broad range of radiation exposures, the present study explored the total-body irradiation (TBI) conditions needed for engraftment in a canine model by using marrow from DLA-identical littermates. Previous studies have shown that such grafts are consistently successful when recipients are exposed to 920 cGy of TBI delivered at a rate of 7 cGy/min from opposing dual cobalt sources. The present TBI doses were all in the lethal range. Five dogs were administered 450 cGy; seven dogs, 600 cGy; five dogs, 700 cGy; and five dogs, 800 cGy of TBI administered at 7 cGy/min. They received a median of 3.3 x 10(8) marrow cells/kg intravenously after completion of radiation. Results showed transient allogeneic marrow engraftment in all dogs administered the lowest dose of TBI studied (450 cGy). Importantly, transient grafts permitted four of five dogs to live long enough for autologous marrow recovery to occur. At increasing radiation doses, 600, 700, and 800 cGy, the risk of graft failure lessened, with 3 of 7, 2 of 5, and 1 of 5 dogs, respectively, showing graft rejection. Fewer dogs survived with autologous marrow recovery, and more showed sustained allogeneic engraftment (4 of 7, 3 of 5, and 4 of 5 dogs, respectively). We conclude that DLA-identical littermate marrow grafts are beneficial in the setting of otherwise lethal radiation exposures, with most dogs either experiencing sustained allogeneic engraftment or surviving with autologous marrow recovery due to the extended support provided by a transient allogeneic graft.
15
Pons, E., R. G. McMahon, M. Banerji, and S. L. Reed. "X-ray properties of z ≳ 6.5 quasars." Monthly Notices of the Royal Astronomical Society 491, no. 3 (November 22, 2019): 3884–90. http://dx.doi.org/10.1093/mnras/stz3275.
Full textAbstract:
ABSTRACT We present XMM–Newton X-ray observations and analysis of three Dark Energy Survey z > 6.5 quasars (VDES J0020−3653 at z = 6.824, VDES J0244−5008 at z = 6.724, and VDES J0224−4711 at z = 6.526) and six other quasars with 6.438 < z < 6.747 from the XMM–Newton public archive. Two of the nine quasars are detected at a high (>4σ) significance level: VDES J0224−4711(z = 6.53) at 9σ and PSO J159−02 (z = 6.38) at 8σ. They have a photon index of $\Gamma =1.82^{+0.29}_{-0.27}$ and $1.94^{+0.31}_{-0.29}$, respectively, which is consistent with the mean value of ∼1.9 found for quasars at all redshifts. The rest-frame 2–10 keV luminosity of VDES J0224−4711 is $L_{2\!-\!10\, \mathrm{keV}} = (2.92\pm 0.43)\times 10^{45}\,\mathrm{erg\,s^{-1}}$, which makes this quasar one of the most X-ray luminous quasars at z > 5.5 and the most X-ray luminous quasar at z > 6.5, with a luminosity 6 times and 2.5 times larger than ULAS J1120+0641 (z = 7.08) and ULAS J1342+0928 (z = 7.54), respectively. The X-ray-to-optical power-law slopes of the nine quasars are consistent with the previously observed anticorrelation of αox with UV luminosity $L_{2500\, \mathrm{\mathring{\rm A} }}$. We find no evidence for evolution of αox with redshift when the anticorrelation with UV luminosity is taken into account. Similar to previous studies at z ∼ 6, we have found remarkably consistent X-ray spectral properties between low-redshift quasars (z ∼ 1) and high-redshift quasars. Our results add further evidence to the picture that the observable properties of high-luminosity quasars over the UV-to-X-ray spectral region have not evolved significantly from z ∼ 7 to the present day and that quasars comparable to local versions existed 800 Myr after the big bang.
16
Hertkorn, Ottmar. "Duden , Band 8: Sinn- und sachverwandte Wörter: Wörterbuch der treffenden Ausdrücke. Hrsg. von Wolfgang Müller. 2. , neu bearbeitete und erweiterte Auflage. Mannheim : Bibliographisches Institut, 1986. - ISBN 3-411-20908-9. 801 Seiten, DM 32." Informationen Deutsch als Fremdsprache 14, no. 5-6 (December 1, 1987): 450–52. http://dx.doi.org/10.1515/infodaf-1987-145-625.
Full text
17
Quinn, Thomas, Randall P. Perrine, Derek C. Richardson, and Rory Barnes. "A SYMPLECTIC INTEGRATOR FOR HILL'S EQUATIONS." Astronomical Journal 139, no. 2 (January 14, 2010): 803–7. http://dx.doi.org/10.1088/0004-6256/139/2/803.
Full text
18
Sartor, A. Oliver, Daniel Heinrich, Svein Inge Helle, Joe M. O'Sullivan, Sophie D. Fossa, Ales Chodacki, Tomasz Demkow, et al. "Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA)." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 9. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.9.
Full textAbstract:
9 Background: Radium-223 chloride (Ra-223) is a 1st-in-class alpha-pharmaceutical targeting bone metastases (mets) with high-energy alpha-particles of short range (<100 μm). ALSYMPCA, a phase III, double-blind, randomized, multinational study, compared Ra-223 plus best standard of care (BSC) vs placebo (pbo) plus BSC in patients (pts) with bone mets in CRPC. The primary endpoint was OS; secondary endpoints included skeletal-related events (SREs). Methods: Eligible pts had progressive, symptomatic CRPC with ≥ 2 bone mets on scintigraphy and no known visceral mets; were receiving BSC; and either previously received docetaxel, were docetaxel ineligible, or refused docetaxel. Pts were randomized 2:1 to receive 6 injections of Ra‐223 (50 kBq/kg IV) q4 wks or matching pbo and stratified by prior docetaxel use, baseline alkaline phosphatase level, and current bisphosphonate use. Results: 922 pts (Ra-223, n = 615; pbo, n = 307) were randomized from 6/2008-2/2011. Based on data from a planned interim analysis (n = 809), unblinded June 2011, Ra-223 significantly improved OS in pts with CRPC with bone mets vs pbo (median OS 14.0 vs 11.2 mo, respectively; two-sided P = 0.00185; HR = 0.695; 95% CI, 0.552-0.875). SREs were lower in the Ra-223 vs pbo group, and time to 1st SRE was significantly delayed (median time to SRE 13.6 mo vs 8.4 mo, respectively; P = .00046; HR = .610; 95% CI, .461-.807). Conclusions: Ra-223 significantly delayed time to 1st SRE and SRE components, except surgical intervention. These reductions in SREs, particularly SCC, are noteworthy. Ra-223 is an effective therapy with a highly favorable safety profile and may provide a new standard of care for treatment of CRPC pts with bone mets. [Table: see text]
19
Lee, Chung-Hyo, Seong-Hee Lee, Sung-Yong Chun, and Sang-Jin Lee. "Fabrication of Mg2Si Thermoelectric Materials by Mechanical Alloying and Spark-Plasma Sintering Process." Journal of Nanoscience and Nanotechnology 6, no. 11 (November 1, 2006): 3429–32. http://dx.doi.org/10.1166/jnn.2006.17955.
Full textAbstract:
A mixture of pure Mg and Si powders with an atomic ratio 2:1 has been subjected to mechanical alloying (MA) at room temperature to prepare the Mg2Si thermoelectric material. Mg2Si intermetallic compound with a grain size of 50 nm can be obtained by MA of Mg66.7Si33.3 powders for 60 hours and subsequently annealed at 620 °C. Consolidation of the MA powders was performed in a spark plasma sintering (SPS) machine using graphite dies up to 800–900 °C under 50 MPa. The shrinkage of consolidated samples during SPS was significant at about 250 °C and 620 °C. X-ray diffraction data shows that the SPS compact from 60 h MA powders consolidated up to 800 °C consists of only nanocrystalline Mg2Si compound with a grain size of 100 nm.
20
Adharini, Wahyu Isnia, Ruri Vivian Nilamsari, Noviana Dwi Lestari, Nashi Widodo, and Muhaimin Rifa'i. "The Role of Moringa oleifera- Ifalmin® Formulation in Regulation of B220+IgM+ and B220+IgG+ in Diabetic Mice." Journal of Experimental Life Sciences 10, no. 1 (June 30, 2020): 43–48. http://dx.doi.org/10.21776/ub.jels.2019.010.01.08.
Full textAbstract:
It has been known that the immunoglobulin levels were altered in diabetes mellitus (DM) conditions. This study aimed to evaluate the levels of immunoglobulins in DM mice after the administration of Moringa oleifera-Ifalmin® formulation (MI). Streptozotocin, at a dose of 145 mg.kg-1, was injected intraperitoneally to experimental mice to obtain diabetic mice. The groups were divided into normal mice, diabetic mice without treatment, diabetic mice with metformin treatment (307.5 mg.kg-1 BW), and diabetic mice with MI treatment at dose 1 (M:I= 800 mg.kg-1 BW: 800 mg.kg-1 BW), dose 2 (M:I= 615 mg.kg-1 BW: 615 mg.kg-1 BW), and dose 3 (M:I= 800 mg.kg-1 BW: 615 mg.kg-1 BW). Mice were orally treated by MI for 14 days. Subsequently, the levels of immunoglobulin IgM and IgG were evaluated using flow cytometry analysis. IgM and IgG levels were significantly lower in the DM group than the normal group. These results indicated that DM altered immunoglobulin levels. MI treatment for 14 days significantly increased the number of IgM and IgG at the level equivalent to the normal group and significantly different as compared to the DM group. Based on the results, MI can be used as an immunomodulatory agent in humoral immunity through the precise regulation of IgM and IgG.
21
Harbage, James F., and Dennis P. Stimart. "THE INFLUENCE OF pH ON AUXIN-INDUCED ADVENTITIOUS ROOT INITIATION IN MALUS DOMESTICA." HortScience 25, no. 9 (September 1990): 1124b—1124. http://dx.doi.org/10.21273/hortsci.25.9.1124b.
Full textAbstract:
Many physiological responses in plants are influenced by pH. The present chemiosmotic hypothesis suggests that auxin uptake into plant cells is governed by pH. Since auxin is used widely to enhance rooting, the influence of pH on 1H-indole-3-butyric acid (IBA) induced adventitious root formation was examined. Roots were initiated aseptically in 5 node apical shoot cuttings of micropropagated Malus domestica 'Gala'. Initiation was induced using a four day pulse in IBA and 15 g/L sucrose at pH 5.6 and 30C in the dark. Observations showed pH rose to 7.0 or greater within 1 to 2 days from microcutting placement in unbuffered initiation medium. Root numbers from shoots in media containing 1.5 μM IBA buffered with 10 mM 2[N-morpholino] ethanesulfonic acid (MES) to pH 5.5, 6.0, 6.5 or 7.0 with KOH resulted in average root numbers of 14.2, 10.9, 8.7, and 7.1, respectively, while unbuffered medium yielded 7,6 roots per shoot. Comparison of MES buffered medium at pH 5.5, 6.25 or 7.0 in factorial combination with IBA at 0, 0.15, 1.5, 15.0, and 150.0 μM resulted in a significant pH by IBA interaction for root number. At 0, 0.15 and 1.5 μM IBA root numbers were greatest at pH 5.5. At 15.0 μM IBA, pH 6.25 was optimal and at 150.0 μM IBA all three pH levels produced equivalent root numbers. A calorimetric assay to measure IBA removal from the initiation medium by microcuttings of `Gala' and `Triple Red Delicious' showed more IBA removal at pH 5.5 than at pH 7.0. Possible reasons for the effect of pH on adventitious root formation will be discussed.
22
Sklad, P. S. "In situ observations of the amorphous-to-gamma transformation in ion-implanted Al2O3." Proceedings, annual meeting, Electron Microscopy Society of America 47 (August 6, 1989): 654–55. http://dx.doi.org/10.1017/s0424820100155244.
Full textAbstract:
Transmission electron microscopy (TEM) was used in an investigation of the recrystallization behavior of amorphous surface layers on single crystal [0001] α-Al2O3. Conventional imaging and diffraction techniques were used to characterize the microstructures produced by annealing bulk specimens in the temperature range from 800°C to 1200°C. It was found that the amorphous Al2O3 first transforms to γ-Al2O3, a cubic transitional form, which in turn transforms to α-Al2O3. The γ to α transformation begins at the original crystalline-amorphous interface and proceeds toward the specimen surface. By measuring the position of the γ-α interface as a function of annealing temperature and time it was possible to determine the temperature-dependent velocity of the γ-α transformation front. Assuming a thermally activated process, the data are consistent with an activation energy of 3.6 eV for the transformation. However, no amorphous material remained, after even the shortest anneals (15 min) at the lowest temperature (800°C). These results indicate that the kinetics of the amorphous to γ transformation are faster than those of the γ to α transformation. Therefore a series of in-situ experiments was carried out to investigate the transformation of amorphous Al2O3 to γ-Al2O3. Amorphous Al2O3 surface layers, free of implanted impurities, were produced by implantation at −185°C with 2 × 1016 Al/cm2 at 90 keV and 3 × 1016 O/cm2 at 55 keV. Cross-sectioned specimens were prepared following established techniques.2 The specimens were annealed in-situ in a Philips CM12 operating at 120 kV with a Gatan Model 628 single tilt heating holder. Progress of the transformations was monitored with a Gatan model 622 video system.
23
Beringer, Richard E. "Media Review." Teaching History: A Journal of Methods 13, no. 2 (May 5, 1988): 76–79. http://dx.doi.org/10.33043/th.13.2.76-79.
Full textAbstract:
Leaders of the 20th Century. 26 videocassettes, each 24 minutes. Film study guides for each film and a companion volume. Available in 1/2" VHS, 1/2" Beta I or II, and 3/4" U-Matic. Order from Learning Corporation of America, 108 Wilmot Road, Deerfield, IL 60015. 1-800-621-2121. $89 per unit ($79 per unit if order ten or more). Review by Richard E. Beringer of the University of North Dakota.
24
Kostev, Karel, Timo Rockel, and Louis Jacob. "Impact of Disease Management Programs on HbA1c Values in Type 2 Diabetes Patients in Germany." Journal of Diabetes Science and Technology 11, no. 1 (July 10, 2016): 117–22. http://dx.doi.org/10.1177/1932296816651633.
Full textAbstract:
Background: The aim was to analyze the impact of disease management programs on HbA1c values in type 2 diabetes mellitus (T2DM) patients in Germany. Methods: This study included 9017 patients followed in disease management programs (DMPs) who started an antihyperglycemic treatment upon inclusion in a DMP. Standard care (SC) patients were included after individual matching (1:1) to DMP cases based on age, gender, physician (diabetologist versus nondiabetologist care), HbA1c values at baseline, and index year. The main outcome was the share of patients with HbA1c <7.5% or 6.5% after at least 6 months and less than 12 months of therapy in DMP and SC groups. Multivariate logistic regression models were fitted with HbA1c level as a dependent variable and the potential predictor (DMP versus SC). Results: The mean age was 64.3 years and 54.7% of the patients were men. The mean HbA1c level at baseline was equal to 8.7%. In diabetologist practices, 64.7% of DMP patients and 55.1% of SC patients had HbA1c levels <7.5%, while 23.4% of DMP patients and 16.9% of SC patients had HbA1c levels <6.5% ( P values < .001). By comparison, in general practices, 72.4% of DMP patients and 65.7% of SC patients had HbA1c levels <7.5%, while 29.0% of DMP patients and 25.4% of SC patients had HbA1c levels <6.5% ( P values < .001). DMPs increased the likelihood of HbA1c levels lower than 7.5% or 6.5% after 6 months of therapy in both diabetologist and general care practices. Conclusion: The present study indicates that the enrollment of T2DM patients in DMPs has a positive impact on HbA1c values in Germany.
25
Chanthima, Natthakridta, and Narong Sangwaranatee. "Upconversion Luminescence and Optical Studies of Nd3+: Bi2O3–B2O3–P2O5 Glasses." Advanced Materials Research 979 (June 2014): 390–94. http://dx.doi.org/10.4028/www.scientific.net/amr.979.390.
Full textAbstract:
The bismuth borophosphate glass matrix doped with Nd2O3have been prepared by conventional melt quenching method with the molar compositions of 25Bi2O3: 5B2O3: (70-x)P2O5: xNd2O3(where x = 0.2, 0.4, 0.6, 0.8 and 1.0 mol%). The density, molar volume, optical absorption and upconversion luminescnece spectra were studied. It can be seen that the density is not depend on Nd2O3concentration. The molar volume is tending to be decreased with increasing of Nd2O3due to the decrease in the bond length or interatomic spacing between the atoms. Ten absorption bands at 427, 471, 510, 525, 580 , 622, 682, 743, 802 and 873 nm are observed, which could be ascribed to Nd3+transitions from the4I9/2ground state to2P1/2,2G9/2,4G9/2,4G7/2,4G5/2+2G7/2,2H11/2,4F9/2,4F7/2+4S3/2,4F5/2+4H9/2and4F3/2levels. The upconversion luminescence band at 394 nm was observed and the highest emission intensity was obtained at 0.8 mol% of Nd2O3.
26
Belmonte Rivas, M., P. Veefkind, H. Eskes, and P. Levelt. "OMI tropospheric NO<sub>2</sub> profiles from cloud slicing: constraints on surface emissions, convective transport and lightning NO<sub>x</sub>." Atmospheric Chemistry and Physics Discussions 15, no. 6 (March 17, 2015): 8017–72. http://dx.doi.org/10.5194/acpd-15-8017-2015.
Full textAbstract:
Abstract. We derive a global climatology of tropospheric NO2 profiles from OMI cloudy observations for the year 2006 using the cloud slicing method on six pressure levels centered about 280, 380, 500, 620, 720 and 820 hPa. A comparison between OMI and the TM4 model tropospheric NO2 profiles reveals striking overall similarities, which confer great confidence to the cloud-slicing approach, along with localized discrepancies that seem to probe into particular model processes. Anomalies detected at the lowest levels can be traced to deficiencies in the model surface emission inventory, at mid tropospheric levels to convective transport and horizontal advective diffusion, and at the upper tropospheric levels to model lightning NOx production and the placement of deeply transported NO2 plumes such as from the Asian summer monsoon. The vertical information contained in the OMI cloud-sliced NO2 profiles provides a global observational constraint that can be used to evaluate chemistry transport models (CTMs) and guide the development of key parameterization schemes.
27
He, Shoucheng, Lanqing Zhang, Jiantao Cai, Xingyu Wu, Hanxi Sun, and Tao Du. "Synthesis and Evaluation of LaBaCo2−xMoxO5+δ Cathode for Intermediate-Temperature Solid Oxide Fuel Cells." Materials 15, no. 17 (August 25, 2022): 5858. http://dx.doi.org/10.3390/ma15175858.
Full textAbstract:
LaBaCo2−xMoxO5+δ (LBCMx, x = 0–0.08) cathodes synthesized by a sol-gel method were evaluated for intermediate-temperature solid oxide fuel cells. The limit of the solid solubility of Mo in LBCMx was lower than 0.08. As the content of Mo increased gradually from 0 to 0.06, the thermal expansion coefficient decreased from 20.87 × 10−6 K−1 to 18.47 × 10−6 K−1. The introduction of Mo could increase the conductivity of LBCMx, which varied from 464 S cm−1 to 621 S cm−1 at 800 °C. The polarization resistance of the optimal cathode LBCM0.04 in air at 800 °C was 0.036 Ω cm2, reduced by a factor of 1.67 when compared with the undoped Mo cathode. The corresponding maximum power density of a single cell based on a YSZ electrolyte improved from 165 mW cm−2 to 248 mW cm−2 at 800 °C.
28
Murkamilov, Ilkhom T., K. A. Aitbaev, and R. Kaliev. "Peculiarities of progression of chronic glomerulonephritis associated with anemia." Clinical Medicine (Russian Journal) 94, no. 8 (October 3, 2016): 620–23. http://dx.doi.org/10.18821/0023-2149-2016-94-8-620-623.
Full textAbstract:
Aim.To study the influence of renal anemia on the clinical course of chronic kidney disease in patients with chronic glomerulonephritis (CGN) at the early stage of the disease. Materials and methods. This prospective 12 month study included evaluation of clinical and laboratory characteristics of 149 patients aged 17-66 (mean 37,6±12,6) years at the pre-dialysis stage of CGN (92 men (37,04±13,4 yr) and 57 women (38,2±11,2 yr). Results. By the end ofprospective observation, patients of group 1 (CGN without anemia) showed a decrease of the hemoglobin level accompanied by the impairment of nitrogenreleasing function with the glomerular filtration rate of 70,1 (43,1-111) ml/min compared with 87 (61,3-115,3) at the onset of observations (p<0,05). In group 2 (CGN with anemia), dynamics of the nitrogen-releasing function was similar but even more pronounced with the glomerular filtration rate reduced to 47,4 (32,2-91,8) ml/mincompared with 80,7 (39,8-107,9) at the onset of observations (p<0,05) and the serum creatinine level increased to157 (92-242) mcmol/l compared with 123 (86-171) (p<0,05). Conclusion. Reduction of hemoglobin level in patients with CGN is apparent at the early stages of the disease in association with impairment of glomerular filtration. The data obtained indicate that anemia can be a laboratory predictor of deteriorated nitrogen-releasing function.
29
Zhang, Zhi Yong, Yong Yang, and Wei Li. "Synthesis and Luminescent Properties of Eu3+ Doped Double Molybdate Phosphors." Advanced Materials Research 211-212 (February 2011): 213–16. http://dx.doi.org/10.4028/www.scientific.net/amr.211-212.213.
Full textAbstract:
A series of trivalent europium (Eu3+) doped double molybdate phosphors (MLa(MoO4)2, M = Li, Na, K) have been prepared via traditional solid state reaction method at 500-800 °C. Their crystal structures and luminescent properties have been investigated, finding that the phosphors take on single phase through X-ray diffraction patterns (XRD) sintered at 600, 700 and 800 °C for lithium, soldium and potassium salt, respectively.Their excited spectra consist of a broad band and three absorptions, in which the higher peaks locate at 400 nm and 470 nm in the region of 350-500 nm. Excited with 470 nm, the emission spectra are composed of four narrow bands and the strongest emission peak is located at 615 nm. The appropriate doping concentration of Eu3+was 10 mol% for the 615 nm emission. The results indicate that this Eu3+activated NaLa(MoO4)2phosphors are promising yellowish red phosphor for ultraviolet (UV) and blue InGaN-based white LED.
30
Al-Batran, Salah-Eddin, Martin H. Schuler, Zanete Zvirbule, Georgiy Manikhas, Florian Lordick, Andriy Rusyn, Yuriy Vynnyk, et al. "FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma." Journal of Clinical Oncology 34, no. 18_suppl (June 20, 2016): LBA4001. http://dx.doi.org/10.1200/jco.2016.34.18_suppl.lba4001.
Full textAbstract:
LBA4001 Background: Claudin18.2 (CLDN18.2) is a tight junction protein expressed by several cancers including gastric and GEJ adenocarcinoma. IMAB362 is a chimeric monoclonal antibody that mediates specific killing of CLDN18.2-positive cancer cells by activation of immune effector mechanisms. IMAB362 has demonstrated single-agent activity and was safe and tolerable in patients (pts) with pretreated gastric cancer. Methods: Pts with advanced/recurrent gastric and GEJ cancer were centrally evaluated for CLDN18.2 expression by IHC (validated CLAUDETECT18.2 Kit). Eligible pts had a CLDN18.2 expression of ≥ 2+ in ≥ 40% tumor cells, an ECOG PS of 0–1 and were not eligible for trastuzumab. Pts were randomized 1:1 to first-line EOX (epirubicin 50 mg/m2 and oxaliplatin 130 mg/m2 d1, and capecitabine 625 mg/m2 bid, d1–21; qd22) with or without IMAB362 (loading dose 800 mg/m2, then 600 mg/m2 d1, qd21). The study was extended by an exploratory Arm3 (N = 85) to investigate a high dose IMAB362 (1000 mg/m2) plus EOX, (not subject here). The primary study endpoint was PFS (Arm 1 v 2, 70% power, HR 0.72, 1-sided p = 0.1). Results: 730 pts were consented, of whom 352 pts (48%) were tested CLDN18.2+ per protocol criteria. Of those, 161 pts (median age, 58 yrs; male 64%; gastric, 80%; GEJ, 16%; esophageal, 4%) were randomized into Arms1 and 2. The study met its endpoints. IMAB362 plus EOX improved PFS (median 5.7 v 7.9 mon; HR 0.5; 95% CI 0.35–0.78, 1-sided p = 0.001) and OS (median 8.7 v 12.5 mon; HR 0.5, 95% CI 0.28–0.73) compared to EOX alone. In the subpopulation with very high CLDN18.2 expression ( ≥ 2+ intensity in ≥ 70% tumor cells), efficacy was more pronounced (PFS, 6.1 vs 9.1 mon; HR 0.46; OS, 9.3 v 16.6 mon; HR 0.44). Most common IMAB362-related adverse events included vomiting, neutropenia, and anemia, which were mostly of NCI-CTC grade 1/2. Grade 3/4 events were not significantly increased by IMAB362. Conclusions: IMAB362 combined with first-line chemotherapy exhibited a clinically relevant benefit in PFS and OS and a favorable risk/benefit profile. Clinical trial information: NCT01630083.
31
Pedro, J. B., S. O. Rasmussen, and T. D. van Ommen. "Rapid coupling of Antarctic temperature and atmospheric CO<sub>2</sub> during deglaciation." Climate of the Past Discussions 8, no. 1 (February 20, 2012): 621–36. http://dx.doi.org/10.5194/cpd-8-621-2012.
Full textAbstract:
Abstract. Antarctic ice cores provide clear evidence of a close coupling between variations in Antarctic temperature and the atmospheric concentration of CO2 during the glacial/interglacial cycles of the past 800 thousand years. Precise information on the relative timing of the temperature and CO2 changes can assist in refining our understanding of the physical processes involved in this coupling. Here, we focus on the last deglaciation, 19 000 to 11 000 years before present, during which CO2 concentrations increased by ~80 parts per million by volume and Antarctic temperature increased by ~10 °C. Utilising a recently developed proxy for regional Antarctic temperature, derived from five near-coastal ice cores, and two ice core CO2 records with high dating precision, we show that the increase in CO2 lagged the increase in regional Antarctic temperature by only 0–400 years. This new value for the lag, consistent for both CO2 records, implies a faster feedback between temperature and CO2 than the centennial to millennial-scale lags suggested by previous studies.
32
Insiripong, S., S. Kaewjeang, U. Maghanemi, H. J. Kim, N. Chanthima, and J. Kaewkhao. "NIR and Upconversion Luminescence Properties of Nd3+ Doped in Gd2O3-CaO-SiO2-B2O3 Glass System." Applied Mechanics and Materials 548-549 (April 2014): 124–28. http://dx.doi.org/10.4028/www.scientific.net/amm.548-549.124.
Full textAbstract:
In this work, properties of Nd3+ in Gd2O3-CaO-SiO2-B2O3 glass systems with composition 25Gd2O3-10CaO-10SiO2-(55-x)B2O3-xNd2O3 where x = 0.0, 0.5, 1.0, 1.5, 2.0 and 2.5 mol% were investigated. The optical absorption spectra show peaks at 4F3/2 (877 nm) , 4F5/2+2H9/2 (802 nm), 4F7/2+4S3/2 (743 nm), 4F9/2 (682 nm), 2H11/2 (627 nm), 2G7/2 +4G5/2 (582 nm), 4G7/2 +2K13/2 (527 nm), 4G11/2 (481 nm), 2P1/2 (427 nm) and 2L15/2 + 4D1/2 + 1I11/2+ 4D5/2+ 4D3/2 (355 nm) reflecting the Nd3+ ions in glass matrices. The densities were increased with increasing of Nd2O3 concentration. This indicates the increase of the molecular weight by the replacement of B2O3 with a heavier Nd2O3 oxide in the glass. The upconversion luminescence spectra show bands at 393 nm for all Nd2O3 concentration and the strongest intensity from 2.5 % mol of Nd2O3 was obtained. For NIR luminescence, the intensity of Nd3+ emission spectra increases with increasing concentrations of Nd3+ up to 1.5 mol% and beyond 1.5 mol% the concentration quenching is observed.
33
Fasler, Katrin, Dun Jack Fu, Gabriella Moraes, Siegfried Wagner, Eesha Gokhale, Karsten Kortuem, Reena Chopra, et al. "Moorfields AMD database report 2: fellow eye involvement with neovascular age-related macular degeneration." British Journal of Ophthalmology 104, no. 5 (October 14, 2019): 684–90. http://dx.doi.org/10.1136/bjophthalmol-2019-314446.
Full textAbstract:
Background/AimsNeovascular age-related macular degeneration (nAMD) is frequently bilateral, and previous reports on ‘fellow eyes’ have assumed sequential treatment after a period of treatment of the first eye only. The aim of our study was to analyse baseline characteristics and visual acuity (VA) outcomes of fellow eye involvement with nAMD, specifically differentiating between sequential and non-sequential (due to macular scarring in the first eye) antivascular endothelial growth factor treatment and timelines for fellow eye involvement.MethodsRetrospective, electronic medical record database study of the Moorfields AMD database of 6265 patients/120 286 single entries with data extracted between 21 October 2008 and 9 August 2018. The data set for analysis consisted of 1180 sequential, 807 non-sequential and 3410 unilateral eyes.ResultsMean VA (ETDRS letters±SD) of sequentially treated fellow eyes at baseline was significantly higher (63±13), VA gain over 2 years lower (0.37±14) and proportion of eyes with good VA (≥70 letters) higher (46%) than the respective first eyes (baseline VA 54±16, VA gain at 2 years 5.6±15, percentage of eyes with good VA 39%). Non-sequential fellow eyes showed baseline characteristics and VA outcomes similar to first eyes. Fellow eye involvement rate was 32% at 2 years, and median time interval to fellow eye involvement was 71 (IQR: 27–147) weeks.ConclusionThis report shows that sequentially treated nAMD fellow eyes have better baseline and final VA than non-sequentially treated eyes after 2 years of treatment. Sequentially treated eyes also had a greater proportion with good VA after 2 years.
34
Jimeno, Cecilia, Rosa Allyn Sy, Pepito De La Pena, Chritopher Cipriano, Rima Tan, Araceli Panelo, and Junice Yi Siu Ng. "Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys." BMJ Open 11, no. 10 (October 2021): e049737. http://dx.doi.org/10.1136/bmjopen-2021-049737.
Full textAbstract:
ObjectiveTo estimate the annual direct medical cost of type 2 diabetes mellitus (T2DM) in hospitals and outpatient care clinics from a healthcare payer perspective in the Philippines.Design and participants(1) A review of electronic hospital records of people with T2DM in two tertiary hospitals—Ospital ng Makati (OsMak) and National Kidney and Transplant Institute (NKTI) and (2) a cross-sectional survey with 50 physicians providing outpatient care for people with T2DM.SettingPrimary, secondary and tertiary healthcare facilities in Metro Manila.Outcome measuresCost of managing T2DM and its related complications in US dollars (USD) in 2016.ResultsA total of 1023 and 1378 people were identified in OsMak and NKTI, with a complication rate of 66% and 74%, respectively. In both institutions, the average annual cost per person was higher if individuals were diagnosed with any complication (NKTI: US$3226 vs US$2242 and OsMak: US$621 vs US$127). Poor diabetes control was estimated to incur higher per person cost than good control in both public outpatient care (poor control, range: US$727 to US$2463 vs good control, range: US$614 to US$1520) and private outpatient care (poor control, range: US$848 to US$2507 vs good control, range: US$807 to US$1603).ConclusionThe results highlight the high direct medical cost resulting from poor diabetes control and the opportunity for cost reduction by improving control and preventing its complications.
35
Bzowska, Agnieszka, and David Shugar. "Properties of 5′-AMP Deaminase and its Inhibitors with the Aid of a Continuous Fluorimetric Assay with Formycin-5′-phosphate as Substrate." Zeitschrift für Naturforschung C 44, no. 7-8 (August 1, 1989): 581–89. http://dx.doi.org/10.1515/znc-1989-7-808.
Full textAbstract:
A new continuous fluorimetric assay for AMP deaminase activity is described. The m ethod makes use of a fluorescent analog of 5′-AMP, formycin-5′-phosphate (5′-FM P), which undergoes deam ination to formycin B-5′-phosphate, not fluorescent at neutral pH. The pH -dependence for deamination of 5′-FMP is similar to that for 5′-AMP, but shifted about 0.2 units to more acidic pH. Deamination of 5′-FM P may also be followed spectrophotometrically at 306 nm, permitting better assays of crude extracts. Some kinetic results obtained by means of the new method for AMP deaminase from chick and rabbit skeletal muscle are presented. In particular it was found that the natural product of deamination, 5′-IMP exhibited allosteric inhibition of the chick enzyme with K, values 1.6mM , 1.2mM and 1.0mM at pH 5.8, 6.5 and 7.3, respectively. Activation by diadenosine tetraphosphate, Ap4A , reported for mouse muscle AMP deaminase, has not been noted for the chick enzyme. Inhibition by the transition state analogs, coformycin and 2′-deoxycoformycin, was observed for both rabbit and chick deaminases with Ki values ~ 1 μM and ~ 1.6 μM respectively. Kinetic data for coformycin-5′-phosphate show it to be a tight-binding inhibitor with K, < 0.6 × 10-9 M as compared to 1 × 10-9 m for 2′-deoxycoformycin-5′-phosphate.
36
HOSSEIN-ZADEH, N. G. "Estimation of genetic parameters and genetic change for stillbirth in Iranian Holstein cows: a comparison between linear and threshold models." Agricultural and Food Science 20, no. 4 (January 4, 2011): 287–97. http://dx.doi.org/10.23986/afsci.6025.
Full textAbstract:
Data on stillbirth from the Animal Breeding Center of Iran collected from January 1990 to December 2007 and comprising 668810 Holstein calving events from 2506 herds were analyzed. Linear and threshold animal and sire models were used to estimate genetic parameters and genetic trends for stillbirth in the first, second, and third parities. Mean incidence of stillbirth decreased from first to third parities: 23.7%, 22.1%, and 21.8%, respectively. Phenotypic rates of stillbirth decreased from 1993 to 1998, for first, second and third calvings, and then increased from 1998 to 2007 for the first three parities. Direct heritability estimates of stillbirth for parities 1, 2 and 3 ranged from 2.2 to 8.7%, 0.6 to 5.1% and 0.1 to 3.8%, respectively, and maternal heritability estimates of stillbirth for parities 1, 2 and 3 ranged from 1.4 to 6.3%, 0.5 to 4.2% and 0.08 to 2.0%, respectively, using linear and threshold animal models. The threshold sire model estimates of heritabilities for stillbirth in this study were 0.021 to 0.071, while the linear sire model estimates of heritabilities for stillbirth in the current study were from 0.003 to 0.021 over the parities. There was a slightly increasing genetic trend for stillbirth rate in parities 1 and 2 over time with the analysis of linear animal and linear sire models. There was a significant decreasing genetic trend for stillbirth rate in parity 1 and 3 over time with the analysis of threshold animal and threshold sire models, but the genetic trend for stillbirth rate in parity 2 with these models of analysis was significantly positive. The low estimates of heritability obtained in this study implied that much of the improvement in stillbirth could be attained by improvement of production environment rather than genetic selection.;
37
Astafyeva, Ludmila I., Boris A. Kadashev, Pavel L. Kalinin, Maxim A. Kutin, Yuliya G. Sidneva, Denilbek B. Ismailov, Ilya V. Chernov, Dina A. Yatsenko, and Larisa K. Dzeranova. "Cerebrospinal fluid rhinorrhoea in young women after 6.5 years of therapy giant prolactinoma with Cabergolin." Endocrine Surgery 11, no. 4 (March 3, 2018): 201–8. http://dx.doi.org/10.14341/serg9485.
Full textAbstract:
Cerebrospinal fluid (CSF) leak is a rare complication in of the prolactinomas treatment with dopamine agonists. In most cases CSF leak develops within the first three months of treatment starting. The article presents a rare clinical case – later development of CSF leak after pharmacological treatment of giant prolactinoma. Women 29 years with giant endo-supra-infra-laterasellar pituitary adenoma (8,7 cm in diameter), visual impairment, cachexia, secondary amenorrhea and prolactin level more than 2 million 200 thousand mU/l treated with cabergoline. On this background, complete regression of the tumor, recovery of visual function, body mass and normalization of prolactin level was marked. Nevertheless, after 6.5 years after beginning of cabergoline therapy CSF leak occured, which required endoscopic endonasal surgery with the plastic of a CSF fistula. All patients with large and giant prolactinomas which invade into skull base structures, receiving cabergoline even for a long time, should be aware of the possibility of such complications as CSF leak and, if necessary, should urgent appeals to the otolaryngologist and the neurosurgeon. In this case closure of skull base defect is a main tactics of treatment.
38
Christiansen, N. P., R. Mena, Y. Markan, and L. Pandit. "A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, cytoxan, and rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell non-Hodgkin lymphoma (NHL) or bulky stage II lymphoma." Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007): 8071. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.8071.
Full textAbstract:
8071 Background: The decision to treat indolent B-cell NHL is often based on progressive disease, worsening symptoms, and increasing hematological variations. When treatment is indicated, these lymphoproliferative disorders are very sensitive to combination chemotherapies. Combination therapy with these agents, pentostatin (P), a purine analog, cyclophosphamide (C), a DNA alkylator, and rituximab (R), an anti-CD20 monoclonal antibody, represents a promising approach in the treatment of these patients. Most regimens have utilized fludarabine (F) as the purine analog but the myelosuppression and immunosuppression of (F) combinations frequently results in severe infections. Methods: Eligibility criteria allow previously treated and treatment-naïve patients diagnosed with bulky stage II or low-grade stage III/IV NHL (REAL classification) to be enrolled. Treatment consisted of intravenous infusions of P (4 mg/m2), C (600 mg/m2), and R (375 mg/m2) on day 1 of a 21-day cycle for a total of up to 10 cycles. Clinical evaluation was performed after cycles 2, 4, 6 and 8 and 10 (if necessary). Results: The intent-to-treat (ITT) population consisted of 87 NHL patients (median age 62.5, range 29–84) who received a total of 476 cycles (median 6 per patient). The ECOG status was 0 (62.4%), 1 (37.6%) and 2 (0%). The overall response rate of the 80 evaluable patients was 72.5% (CR 11.3%, Cru 12.5%, PR 48.8%). 14 cases of grade 4 and 17 cases of grade 3 neutropenia were documented. There were a total of 4 deaths due to acute myocardial infarction, NSCLC, a suspected cardiac event and 1 unknown cause of death. Conclusions: This immunochemotherapeutic regimen is active in indolent Grade III/IV NHL and the incidence of significant toxicities was low. Future trials evaluating the use of rituximab as maintenance therapy following this PCR regimen may also be warranted with a future goal towards possibly increasing the overall survival of patients with NHL. The presented results are preliminary and the study is currently on-going. No significant financial relationships to disclose.
39
Williams, Michael. "Handbook of Pharmaceutical Additives. Michael and Irene Ash, Gower Chemical References, Aldershot, Hampshire, United Kingdom, 1995, xiv + 1118, Book, $350; IBM/WindowsTM Electronic Version, $450; Book + Electronic Format, $625. U.S. distributor, Ashgate Publishing, Brookfield, Vermont. Phone: 800-535-9544." Drug Development Research 38, no. 2 (June 1996): 134. http://dx.doi.org/10.1002/(sici)1098-2299(199606)38:2<134::aid-ddr8>3.0.co;2-k.
Full text
40
Meyer, Romain A., Roberto Decarli, Fabian Walter, Qiong Li, Ran Wang, Chiara Mazzucchelli, Eduardo Bañados, Emanuele P. Farina, and Bram Venemans. "Constraining Galaxy Overdensities around Three z ∼ 6.5 Quasars with ALMA and MUSE." Astrophysical Journal 927, no. 2 (March 1, 2022): 141. http://dx.doi.org/10.3847/1538-4357/ac4f67.
Full textAbstract:
Abstract We quantify galaxy overdensities around three high-redshift quasars with known [C ii]158 μm companions: PJ231–20 (z = 6.59), PJ308–21 (z = 6.24), and J0305–3150 (z = 6.61). Recent SCUBA2 imaging revealed the presence of 17 submillimeter galaxies (SMGs) with sky separations 0.′7 < θ < 2.′4 from these three quasars. We present ALMA Band 6 follow-up observations of these SCUBA2-selected SMGs to confirm their nature and redshift. We also search for continuum-undetected [C ii]158 μm emitters in the ALMA pointings and make use of archival MUSE observations to search for Lyα emitters (LAEs) associated with the quasars. While most of the SCUBA2-selected sources are detected with ALMA in the continuum, no [C ii]158 μm line emission could be detected, indicating that they are not at the quasar redshifts. Based on the serendipitous detection of CO 7–6 and [C i]809 μm emission lines, we find that four SMGs in the field of PJ231–20 are at z ∼ 2.4, which is coincident with the redshift of an Mg ii absorber in the quasar rest-frame UV spectrum. We report the discovery of two LAEs within <0.6 cMpc of PJ231–20 at the same redshift, indicating an LAE overdensity around this quasar. Taken together, these observations provide new constraints on the large-scale excess of Lyα- and [C ii]158 μm-emitting galaxies around z > 6 quasars and suggest that only wide-field observations, such as MUSE, ALMA, or JWST mosaics, can reveal a comprehensive picture of large-scale structure around quasars in the first billion years of the universe.
41
Carabajal, C. C., and J. P. Boy. "ICESAT-2 ALTIMETRY AS GEODETIC CONTROL." ISPRS - International Archives of the Photogrammetry, Remote Sensing and Spatial Information Sciences XLIII-B3-2020 (August 22, 2020): 1299–306. http://dx.doi.org/10.5194/isprs-archives-xliii-b3-2020-1299-2020.
Full textAbstract:
Abstract. Digital elevation models (DEMs) are of fundamental importance for a large variety of scientific and commercial applications. Many geoscience studies require the most precise and current information about the Earth’s topography. Independent quality assessments of these DEMs are crucial to their appropriate use in land process studies, as inputs to models, and for detection of topographic change. The Ice, Cloud and land Elevation Satellite (ICESat) provided globally-distributed elevation data of high accuracy that demonstrated to be well-suited for evaluating continental DEMs after appropriate editing (Carabajal and Harding, 2005; Carabajal and Harding, 2006; Carabajal et al., 2010 and 2011; Carabajal and Boy, 2016). ICESat-2, launched on September 15th, 2018, provides an opportunity to develop a dataset suitable for Geodetic Ground Control. With increased coverage, ICESat-2/ATLAS features 6 laser beams with 532 nm wavelength, using photon counting technologies. With a nearly polar orbit, altimetry from ICESat-2 is available for latitudes reaching up to 88 degrees, on a 91-day repeat orbit with monthly sub-cycles. ICESat-2’s footprint size is ∼17 m, at 10 kHz pulse repetition frequency, or 0.75 m along track. Its pointing control is 45 m, with a pointing knowledge of 6.5 m, and a single photon precision of 800 ps. Sophisticated data processing techniques on the ground, optimized by surface type, produce high quality estimates of topography. We illustrate the use of ICESat-2 altimetry to assess DEM’s accuracy using ATL08 release 002 elevations (Land and Vegetation) products (Neuenschwander and Pitts, 2019), showing comparable results to those using ICESat-derived Geodetic Ground Control.
42
Sohn, Woon-Mok, Byoung-Kuk Na, Shin-Hyeong Cho, Jung-Won Ju, Cheon-Hyeon Kim, Min-Ah Hwang, Kyeong-Woo No, and Jong-Ho Park. "Prevalence and Infection Intensity of Zoonotic Trematode Metacercariae in Fish from Soyang-cheon (Stream), in Wanju-gun, Jeollabuk-do, Korea." Korean Journal of Parasitology 59, no. 3 (June 21, 2021): 265–71. http://dx.doi.org/10.3347/kjp.2021.59.3.265.
Full textAbstract:
We surveyed on the infection status of zoonotic trematode metacercariae (ZTM) in freshwater fishes from Soyang-cheon (a branch stream of Mangyeong-gang) in Wanju-gun, Jeollabuk-do, the Republic of Korea. A total of 927 fishes were individually examined with the artificial digestion method during 2013-2015 (462 fish in 15 spp.) and 2018-2019 (465 fish in 25 spp.). Clonorchis sinensis metacercariae were detected in 207 (31.4%) out of 659 fishes in 14 positive fish species (PFS), and their mean intensity was 114 per fish infected (PFI). Metagonimus spp. metacercariae were found in 302 (37.4%) out of 808 fishes in 21 PFS, and their mean intensity was 12 PFI. Centrocestus armatus metacercariae were detected in 222 (59.0%) out of 376 fishes in 12 PFS, and their mean intensity was 383 PFI. Echinostoma spp. metacercariae were found in 139 (22.1%) out of 628 fishes in 10 PFS, and their mean intensity was 7 PFI. Clinostomum complanatum metacercariae were detected in 14 (6.5%) out of 214 fishes in 4 PFS, and their mean intensity was 2.4 PFI. Metorchis orientalis metacercariae were detected in 36 (13.5%) out of 267 fishes in 5 PFS, and their mean intensity was 4.3 PFI. Conclusively, the prevalence and infection intensity of ZTM is generally not so high in fishes from Soyang-cheon. However, those of C. sinensis metacercariae are more or less higher in 2 fish species, Pungtungia herzi and Sarcocheilichthys variegatus wakiyae.
43
Leite, Paulo J. M., Lolita M. Tsanaclis, Tânia Markourakis, and Paulo Rogério M. Mittencourt. "Doses-carga de carbamazepina e difenil-hidantoína: utilização em pacientes de alto risco." Arquivos de Neuro-Psiquiatria 45, no. 3 (September 1987): 281–87. http://dx.doi.org/10.1590/s0004-282x1987000300008.
Full textAbstract:
Doses-carga de difenil-hidantoína (lOOOmg) e carbamazepina (600mg) foram administradas oralmente a respectivamente 10 e 6 pacientes com crises epilépticas secundárias a doença aguda neurológica ou síndrome de abstinência alcoólica. No grupo da difenil-hidantoína a idade variou de 12 a 73 anos e as concentrações séricas 2, 4, 6, 8, 12 e 18 horas após a administração foram 7,6, 8,8, 8,7, 8,7, 7,2 e 6,5 mg/ml (média). Não foram anotados efeitos colaterais importantes por um método quantitativo. No grupo da carbamazepina a idade variou de 25 a 56 anos e as concentrações séricas nas mesmas horas foram 3,9, 5,3, 6,5, 7,5, 7,4 e 8,2 mg/ml. Efeitos colaterais foram discretos. Não foi necessária medicação suplementar durante as 24 horas após a administração das doses-carga. Embora ambos os esquemas tenham controlado a situação clínica sem efeitos colaterais relevantes, as concentrações séricas foram sub-terapêuticas no caso da difenil-hidantoína. Sugerimos que a dosecarga ideal de difenil-hidantoína é 1500mg. A dose-carga de carbamazepina foi eficaz e produziu níveis séricos terapêuticos. A estabilidade dos níveis séricos durante o período de estudo torna este esquema útil no controle subagudo de crises epilépticas frequentes, no tratamento de manutenção de estado de mal epiléptico e na síndrome de retirada alcoólica.
44
Jaszek, Magdalena, Monika Osińska-Jaroszuk, Grzegorz Janusz, Anna Matuszewska, Dawid Stefaniuk, Justyna Sulej, Jolanta Polak, Marta Ruminowicz, Krzysztof Grzywnowicz, and Anna Jarosz-Wilkołazka. "New Bioactive Fungal Molecules with High Antioxidant and Antimicrobial Capacity Isolated fromCerrena unicolorIdiophasic Cultures." BioMed Research International 2013 (2013): 1–11. http://dx.doi.org/10.1155/2013/497492.
Full textAbstract:
Three bioactive fractions, extracellular laccase (ex-LAC), crude endopolysaccharides (c-EPL), and a low molecular subfraction of secondary metabolites (ex-LMS), were isolated from the idiophasic cultures of the white rot fungusCerrena unicolor. For the first time, we determined the antioxidant properties of these samples by chemiluminometric measurement (a) and assessment of the scavenging effect on ABTS (b) and the DPPH reduction rate (c). The highest reducing capability was found for the ex-LMS fraction: 39–90% for (a), 20–90% for (b), and 10–59% for (c) at the concentration of 6.25–800 µg/mL. The scavenging abilities of theC. unicolorc-EPL were between 36 and 70% for (a), 2 and 60% for (b), and 28 and 32% for (c) at the concentration of 6.25–800 µg/mL. A very high prooxidative potential was observed for the ex-LAC probes. The preliminary toxicity tests were done using the Microtox system and revealed the following percentage of the toxic effect againstVibrio fischeri: 85.37% for c-EPL, 50.67% for ex-LAC, and 99.8% for ex-LMS, respectively. The ex-LAC sample showed the antibacterial activity againstEscherichia coli, c-EPL againstStaphylococcus aureus, and ex-LMS against both bacterial strains, respectively, but the stronger inhibitory effect was exerted onS. aureus.
45
Petrocelli, Giovannamaria, Fulvia Farabegoli, Maria Chiara Valerii, Catia Giovannini, Alberto Sardo, and Enzo Spisni. "Molecules Present in Plant Essential Oils for Prevention and Treatment of Colorectal Cancer (CRC)." Molecules 26, no. 4 (February 8, 2021): 885. http://dx.doi.org/10.3390/molecules26040885.
Full textAbstract:
Essential oils (EOs) are a complex mixture of hydrophobic and volatile compounds synthesized from aromatic plants, commonly present in the human diet. In recent years, many in vitro studies have suggested possible anticancer properties of single EO compounds, on colorectal cancer (CRC) cells. However, the majority of these studies did not compare the effects of these compounds on normal and cancer colon cells. By using NCM-460, a normal human mucosal epithelial cell line, Caco-2, a human colon epithelial adenocarcinoma cell line, and SW-620, colon cancer cells derived from lymph node metastatic site, we identified cinnamaldehyde, derived from cinnamon EO and eugenol, derived from bud clove EO, as compounds with a specific anticancer action selectively targeting the transformed colonic cells. Both cinnamaldehyde (75 µM) and eugenol (800 µM), after 72 h of treatment, were capable to induce apoptosis, necrosis and a cell cycle slowdown in Caco-2 and in SW-620, but not in NCM-460 cells. If associated with a targeted delivery to the colon, these two compounds could prove effective in the prevention or treatment of CRC.
46
Hayashi, Kaori, Seiichiro Mitani, Hiroya Taniguchi, Satoshi Hamauchi, Keiji Sugiyama, Takahiro Tsushima, Kazunori Honda, et al. "Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months." Journal of Clinical Oncology 35, no. 4_suppl (February 1, 2017): 800. http://dx.doi.org/10.1200/jco.2017.35.4_suppl.800.
Full textAbstract:
800 Background: The ASPECCT study showed panitumumab (Pmab) is non-inferior to cetuximab (Cmab) for chemotherapy-refractory and intolerant wild-type (WT) KRAS exon2 metastatic colorectal cancer (mCRC). In the subgroup analysis, Pmab provided more favorable outcomes than Cmab for patients (pts) previously treated with bevacizumab (Bmab). However, some reports suggested that anti-EGFR antibody (anti-EGFR) efficacy was reduced when received within 6 months of last administration of Bmab. In this study, we aim to evaluate the difference in efficacy between Pmab and Cmab in pts who received prior Bmab and were treated with anti-EGFR after a short interval. Methods: We retrospectively evaluated pts treated with anti-EGFR and irinotecan (IRI) after failure of Bmab, fluoropyrimidine, oxaliplatin, and IRI at two institutions. The main inclusion criteria were WT KRAS exon2 mCRC, ECOG PS 0-2, and no prior administration of anti-EGFR within 6 months after Bmab. Results: From Sep. 2008 to Mar. 2016, 124 consecutive pts met the inclusion criteria (Pmab/Cmab, 30/94). Pts’ characteristics were as follows (Pmab/Cmab): median age (range): 63/62 (38-76/27-82); male, 63%/72%; ECOG PS 0, 43%/27%; PS1, 57%/66%; PS2 0%/7%; tumor in left colon, 87%/76%; histology (por, muc), 10%/16%; ≥2 metastases, 67%/66%; ≥1 subsequent therapy, 73%/63%. Overall response and disease control rates in Pmab/Cmab were 31%/26% and 69%/67%, respectively. In Pmab/Cmab, the median overall survival was 15.8/12.2 months (HR, 0.62; 95% CI, 0.4-0.97; P=0.04) and the median progression-free survival was 6.5/5.5 months (HR, 0.75; 95% CI, 0.49-1.16, P=0.20). The adjusted HR with 10 covariates such as age, gender, PS, tumor location, histology, primary tumor resection, number of metastatic sites, liver limited disease, time from diagnosis of metastasis and initiation date of anti-EGFR plus IRI was 0.61 for PFS (p=0.1) and 0.61 for OS (p=0.04). Conclusions: Pmab plus irinotecan showed favorable outcomes compared with Cmab plus irinotecan in pts with WT KRAS exon2 mCRC within 6 months between the last administration of Bmab and initial anti-EGFR.
47
Li, Heng, He Yang, Dan Wang, and Zhi Yong Zhang. "FE-Based Analysis of Heat Bending of Thin-Walled Ti-Alloy Tube with Large Diameter and Small Bending Radius." Advanced Materials Research 622-623 (December 2012): 25–29. http://dx.doi.org/10.4028/www.scientific.net/amr.622-623.25.
Full textAbstract:
The numerical control (NC) heat bending of thin-walled Ti-alloy tube with large diameter and small bending radius with Ф50×1×R75mm (diameter OD bending radius CLR) is explored by 3D-FE thermal-mechanical coupling simulation of heat conducting and NC bending. The results show that: (1) The heating of both pressure die and mandrel is proved to be appropriate to obtain the required temperature field. (2) In terms of wall thickness variation, wrinkling and cross-section deformation, the optimum span of the key parameters are obtained: the bending velocity of 0.4rad/s, the matched pressure die speed of 80%-110%, and temperature of 600-800°C.
48
Hajek, Roman, Luděk Pour, Miquel Granell, Vladimir Maisnar, Paul G. Richardson, Stefan Norin, Malin Sydvander, Jakob Obermüller, and Enrique M. Ocio. "ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results." Journal of Clinical Oncology 39, no. 15_suppl (May 20, 2021): 8037. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.8037.
Full textAbstract:
8037 Background: Development of resistance to standard treatments for RRMM highlights the need for novel therapies. Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate (PDC) that leverages aminopeptidases and rapidly releases alkylating agents inside tumor cells. Melflufen + dex showed clinical activity and an acceptable safety profile in HORIZON (Richardson et al. J Clin Oncol. 2020 Dec 9 [Epub]). This is an update of the BTZ arm of the phase 1/2a ANCHOR study (NCT03481556). Methods: Patients (pts) with RRMM were intolerant or refractory to a prior IMiD, with 1-4 prior lines of therapy (LoTs). Prior treatment with a proteasome inhibitor (PI) was allowed, but pts could not be refractory to PIs in the last LoT. Melflufen (30, 40, or 20 mg intravenously; d 1 of each 28-d cycle) was administered with BTZ (1.3 mg/m2 subcutaneous) + oral dex (20 mg on d 1, 4, 8, and 11 and 40 mg on d 15 and 22; dex dose reduced if aged ≥ 75 y). The primary objective in phase 1 was to determine the optimal phase 2 dose of melflufen for this combination. Results: As of the data cutoff date (October 19, 2020), 13 pts received melflufen (30 mg, n = 6; 40 mg, n = 7) + dex and BTZ. In the 30 mg and 40 mg cohorts, respectively, median age was 78.5 y (range, 70-82) and 70.0 y (range, 61-76); median prior LoTs was 3.5 (range, 2-4) and 2.0 (range, 1-4); 33% and 50% of evaluable pts had high-risk cytogenetics; 83% and 71% were refractory to last LoT; 100% and 86% received a prior PI; 33% and 14% were refractory to PIs. In the 30 mg and 40 mg cohorts, respectively, median treatment duration was 6.5 mo (range, 1.4-29.0) and 8.7 mo (range, 2.1-19.6); 4 (67%) and 4 pts (57%) were still on treatment; 2 and 3 pts discontinued (30 mg: progressive disease [PD] and other [1 pt each]; 40 mg: adverse event [AE], lack of efficacy, and PD [1 pt each]). Confirmed overall response rate in the 30 mg and 40 mg cohorts, respectively, was 50% (1 very good partial response [VGPR] and 2 partial response [PR]) and 71% (1 complete response, 3 VGPR, and 1 PR). Most common grade 3/4 treatment-related AEs (TRAEs) were thrombocytopenia (30 mg: 50%; 40 mg: 100%) and neutropenia (30 mg: 33%; 40 mg: 71%); grade 3/4 nonhematologic TRAEs were infrequent; 3 pts discontinued study treatment due to treatment-emergent AEs (30 mg: cardiac failure chronic and osteolysis [1 pt each]; 40 mg: thrombocytopenia [1 pt]). Serious TRAEs occurred in 2 pts (33%) in the 30 mg cohort (neutropenia and pneumonia [1 pt], syncope [1 pt]) and 1 pt (14%) in the 40 mg cohort (thrombocytopenia and neutropenia). No dose-limiting toxicities occurred at either dose level. Fatal AEs occurred in 1 pt in the 30 mg cohort (cardiac failure chronic; unrelated to study treatment). Conclusions: ANCHOR determined that the optimal dose of melflufen is 30 mg + dex and BTZ; results showed clinical activity in heavily pretreated pts. Recruitment is ongoing; updated data will be presented. Clinical trial information: NCT03481556.
49
Huseinagić, Senad, Selvedina Sarajlić-Spahić, Fatima Bašić, Jasmin Durmišević, and Amir Ibrahimagić. "Characteristics of Symptomatic and Asymptomatic Patients With COVID-19 and Seroprevalence of anti-SARS-CoV-2 Antibodies in Zavidovići, Bosnia and Herzegovina." European Journal of Medical and Health Sciences 4, no. 1 (February 10, 2022): 80–84. http://dx.doi.org/10.24018/ejmed.2022.4.1.1213.
Full textAbstract:
Human coronaviruses are agent which cause respiratory illnesses and have been described to be continously emerging. Seroprevalence of IgM/IgG antibodies was determined by lateral flow immunoassay. Study were include data on participants experience of COVID-19 symptoms during the pandemic (including symptoms and health status). Among 443 serum samples for detection seroprevalence, 186 (42.0%) were seropositive on specific antibodies (IgM/IgG) or participants who had COVID-19 with or without symptoms. Of the seropositive the age group 25-50 years old had the highest percentage (32.8%) followed by 51-64 years (30.6%). Ninety seropositive patients (out of 186; 48.4%) were detected with the specific symptoms. The most frequently symptoms were fever (n=54, out of 90; 60.0%), muscle pain (46.7%), dry cough and loss of smell (36.7%) and others. More than one symptoms were detected in 59 cases (65.6%). The most common comorbidities were diabetes mellitus (n=12, out of 186; 6.5%), than hypertension (nine; 4.8%) and heart diseases (seven; 3.8%). More than half of seropositive were asymptomatic (n=96, out of 186; 51.6%). Note: In period March 2020 - June 2021, among 3323 samples, 804 (24.2%) were positive on SARS-CoV-19 with RT-PCR. The results showed that 394 (out of 804; 49.0%) positive samples were collected from female and 410 (51.0%) from male. The most prevalent of SARS-CoV-19 viruses were detected in > 65 years old (n=267, out of 804; 33.2%). Further research on the contribution of symptomatic or asymptomatic individuals to the community spread of COVID-19 is essential for effective control of the pandemic spread of SARS-CoV-2.
50
Shantha, Ghanshyam Palamaner Subash, Anita Ashok Kumar, Scott Kahan, and Lawrence J. Cheskin. "Association Between Glycosylated Hemoglobin and Intentional Weight Loss in Overweight and Obese Patients With Type 2 Diabetes Mellitus." Diabetes Educator 38, no. 3 (April 16, 2012): 417–26. http://dx.doi.org/10.1177/0145721712443293.
Full textAbstract:
Purpose The purpose of this study is to assess the relationship between magnitude of weight loss and improvement in percentage A1C (A1C%) among overweight and obese patients with type 2 diabetes mellitus (DM) undergoing weight reduction. Methods Case records of patients enrolled in 2 university-based weight management programs were reviewed. Patients were sampled if they had a diagnosis of DM and had at least 1 documented A1C% reduction from their baseline value. Weight loss treatment was individualized and consisted of a calorie-restricted diet, a behavior modification plan, and a plan for increasing physical activity. Patient weights were measured at bimonthly visits. A1C% was measured every 3 months. Results Seventy-two patients formed the study cohort. Mean baseline body mass index was 35.1 kg/m2, mean age was 52.6 years, and 59% were males. Mean starting A1C% was 8.6. Patients achieved significant mean weight loss (10.7 kg) at study exit. Weight loss of 6.5 kg (4.5% of baseline body weight), 12.2 kg (8.7%), and 15.9 kg (10.3%) was required to reduce A1C% by 0.5, 1, and 1.5, respectively, and it took a mean of 5.6, 8.7, and 10.1 months, respectively, to achieve this. After adjustment for antidiabetic medication intake, for every 10% weight loss, the predicted reduction in A1C% was 0.81. Conclusions Intentional weight loss of 10% can potentially decrease A1C% by 0.81 among patients with type 2 DM. This finding may be clinically useful in encouraging and counseling a patient attempting weight loss.